PNC27
Typical Dosing Protocols (Research/Compounded Use Only) – PNC-27
Common protocol: 200–500 mcg subcutaneously once daily for 20–30 consecutive days, followed by a 2–4 week break. Most users start at 200–300 mcg daily and titrate up to 400–500 mcg based on response.
Other reported ranges:
Standard: 250–400 mcg daily
More intensive: 500–1,000 mcg daily (split into 2 doses)
Cycles typically last 20–30 days, repeatable 2–3 times per year with adequate breaks.
Reconstitution example (for a typical 5 mg or 10 mg vial): Add 2 mL bacteriostatic water (yielding ~2.5–5 mg/mL).
200 mcg = 0.04–0.08 mL (4–8 units on U-100 insulin syringe)
500 mcg = 0.1–0.2 mL (10–20 units)
Administration: Subcutaneous injection (abdomen or thigh), usually in the morning or early afternoon. Localized injection near target areas is sometimes reported.
Dosing is highly individualized based on goals and response—consult a qualified healthcare provider experienced with peptides for personalized guidance. This is for informational purposes only.
Key Potential Benefits of PNC-27
Selective Induction of Cancer Cell Necrosis via Membrane Disruption
Binds with high specificity to HDM-2 (MDM2) overexpressed on the plasma membranes of cancer cells, forming transmembrane pores that cause rapid extrusion of intracellular contents and necrotic cell death (membranolysis).
Triggers lysis independent of p53 status (effective in p53-wildtype, mutant, or null cancer cells), providing a broad mechanism that bypasses common resistance pathways in tumor cells.
Demonstrates potent cytotoxicity across diverse cancer cell lines with low IC50 values in many models, achieving near-complete cell killing in short timeframes (e.g., 90 minutes in some solid tumor lines).
Broad Anti-Tumor Activity Against Multiple Cancer Types
Exhibits strong cytotoxic effects against a wide range of solid tissue tumors, including breast, pancreatic, lung, colon, ovarian, cervical (squamous and endocervical), and melanoma models.
Shows efficacy in hematopoietic cancers such as acute and chronic myelogenous leukemia, as well as multiple myeloma, including high-risk or stem-cell-enriched populations.
Supports tumor eradication in preclinical in vivo models (e.g., complete regression of highly metastatic pancreatic tumors and leukemia xenografts in nude mice) with demonstrated selectivity.
Preservation of Normal/Healthy Cell Viability
Displays no significant cytotoxic effects on corresponding untransformed or normal cells (including primary fibroblasts, normal pancreatic acinar cells, and hematopoietic stem cells), even at concentrations lethal to cancer cells.
Maintains differentiation potential of normal stem cells under growth factor stimulation, suggesting compatibility with bone marrow function and tissue homeostasis in research settings.
Enables targeted action that spares non-cancerous tissues, potentially supporting tumor reduction without broad cellular toxicity observed with many conventional agents.
Additional Intracellular Mechanisms Enhancing Cancer Cell Death
Penetrates cancer cells (via formed pores or cell-penetrating sequence) and disrupts mitochondrial membranes, leading to mitochondrial dysfunction, oxidative stress, and amplified necrotic pathways.
Co-localizes with membrane HDM-2 to initiate pore formation while contributing to intracellular effects that accelerate tumor cell elimination.
May complement p53 pathway dynamics by acting as a competitive inhibitor at HDM-2 binding sites, supporting prolonged p53 activity in relevant models.
Potential for Tumor Regression and Metastasis Control in Models
Induces rapid necrosis of primary tumor cells and shows activity against metastatic potential (e.g., eradication of aggressive pancreatic cancer lines in animal xenografts).
Supports reduction in tumor burden across solid and non-solid malignancies, with research indicating effectiveness even in poorly differentiated or therapy-resistant lines.
Explored for synergy with other modalities in preclinical contexts to enhance overall anti-tumor outcomes and limit spread.
Advantages in Selectivity and Research Utility for Oncology
Offers a membrane-active mechanism distinct from apoptosis-inducing agents, potentially overcoming resistance mechanisms tied to caspase pathways or anti-apoptotic proteins.
Demonstrates consistent selectivity tied to elevated membrane HDM-2 expression characteristic of malignant cells, positioning it as a tool for studying targeted necrosis across cancer subtypes.
Contributes to broader exploration of peptide-based strategies for precise tumor cell elimination while maintaining normal cellular integrity in experimental models.
